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Abstract
We previously demonstrated the synergistic therapeutic effect of the cetuximab (anti–epidermal growth factor re-
ceptor [EGFR] monoclonal antibody, mAb)–trastuzumab (anti-HER2 mAb) combination (2mAbs therapy) in HER2low
human pancreatic carcinoma xenografts. Here, we compared the 2mAbs therapy, the erlotinib (EGFR tyrosine kinase
inhibitor [TKI])–trastuzumab combination and lapatinib alone (dual HER2/EGFR TKI) and explored their possiblemecha-
nisms of action. The effects on tumor growth and animal survival of the three therapies were assessed in nude mice
xenografted with the human pancreatic carcinoma cell lines Capan-1 and BxPC-3. After therapy, EGFR and HER2 ex-
pression and AKT phosphorylation in tumor cells were analyzed by Western blot analysis. EGFR/HER2 heterodimer-
ization was quantified in BxPC-3 cells by time-resolved FRET. In K-ras–mutated Capan-1 xenografts, the 2mAbs
therapy gave significantly higher inhibition of tumor growth than the erlotinib/trastuzumab combination, whereas in
BxPC-3 (wild-type K-ras) xenografts, the erlotinib/trastuzumab combination showed similar growth inhibition but fewer
tumor-freemice. Lapatinib showed no antitumor effect in both types of xenografts. The efficacy of the 2mAbs therapy
was partly Fc-independent because F(ab′)2 fragments of the twomAbs significantly inhibited BxPC-3 growth, although
with a time-limited therapeutic effect. The 2mAbs therapy was associated with a reduction of EGFR and HER2 expres-
sion and AKT phosphorylation. BxPC-3 cells preincubated with the two mAbs showed 50% less EGFR/HER2 hetero-
dimers than controls. In pancreatic carcinoma xenografts, the 2mAbs therapy is more effective than treatments
involving dual EGFR/HER2 TKIs. The mechanism of action may involve decreased AKT phosphorylation and/or dis-
ruption of EGFR/HER2 heterodimerization.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer death both in
men and women. Despite many efforts to improve the survival rate,
currently, most patients with pancreatic cancer die within a year of
diagnosis. When the tumor becomes symptomatic, 60% to 80% of
the patients already have locally advanced or metastatic disease [1],
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thus allowing essentially only palliative therapy with a 5-year survival
rate lower than 5% [2]. To find efficient treatments, translational re-
search has investigated the molecular mechanisms implicated in pan-
creatic cancer development. Recent data suggest that a large number of
genetic alterations affect only few major signaling pathways involved
in pancreatic tumorigenesis, such as those associated with members
of the epidermal growth factor receptor (EGFR) family [3] that can
be targeted by novel therapies [4–6]. Dual inhibition of EGFR and
HER2 was proposed for pancreatic carcinoma based on the observed
overexpression of EGFR in 40% to 70% of these cancers, HER2
overexpression in a smaller subset of cases [7,8], and the major role
played by EGFR/HER2 heterodimers [6]. Furthermore, the implica-
tion of EGFR and HER2 in the malignant phenotype of pancreatic
cancer [4,9] paved the way for therapeutic strategies aimed at targeting
both receptors.
Erlotinib, an EGFR tyrosine kinase inhibitor (TKI), was the first
EGFR-targeted therapy approved by the US Food and Drug Adminis-
tration for the treatment of pancreatic carcinoma. The combination of
erlotinib with gemcitabine for pancreatic carcinoma was tested in a
phase 3 clinical trial with modest survival benefit, which, was, however,
better than the results obtained with cetuximab plus gemcitabine [10].
After US Food and Drug Administration approval of the combina-
tion of lapatinib, a dual EGFR/HER2 TKI, and capecitabine for
the treatment of HER2 overexpressing advanced or metastatic breast
carcinoma, three clinical studies to test the effect of lapatinib associated
with chemotherapy in pancreatic carcinoma have been started. Two of
these studies are ongoing clinical trials that assess the combination of
lapatinib and capecitabine as a second-line treatment (NCT00881621)
or inmetastatic pancreatic carcinoma (NCT00962312). The third one is
a phase 1 study that showed that a dosage of 1000 mg/d of lapatinib, in
combination with gemcitabine and/or gemcitabine/oxaliplatin, induced
no excessive toxicity in advanced pancreaticobiliary carcinoma [11].
We have recently shown that two therapeutic antibodies, the anti-
EGFR cetuximab and the anti-HER2 trastuzumab, which are broadly
used separately in the clinic, have a synergistic antitumor effect when
used in combination. They significantly increased survival of mice xeno-
grafted with two different pancreatic carcinoma cell lines, whereas each
antibody had a minor effect on its own [6]. Furthermore, this original
dual EGFR/HER2 targeting strategy with cetuximab and trastuzumab
(2mAbs therapy) was more efficient as first- and second-line treatment
than the standard chemotherapy with gemcitabine [12].
In the present study, we compared the 2mAbs therapy (cetuximab/
trastuzumab) to the combination of erlotinib and trastuzumab and to
lapatinib alone in mice xenografted with two HER2low human pan-
creatic carcinoma cell lines. The 2mAbs therapy induced a marked
and stable down-regulation of EGFR and HER2 and the downstream
blockade of AKT phosphorylation in pancreatic carcinoma cells, whereas
the other treatments had a more transient effect on receptor expression.
Incubation of human pancreatic carcinoma cells with the two mAbs
also induced a 50% disruption of EGFR and HER2 receptors hetero-
dimerization and a crucial increase in homodimers.
Materials and Methods
Materials
The anti-EGFR mAbs cetuximab (human) and m425 (mouse) were
purchased from Merck KGaA (Darmstadt, Germany) and Merck AG
(Frankfurt, Germany), respectively. Trastuzumab and erlotinib were
obtained from Roche Pharma AG (Grenzach-Wyhlen, Germany)
and lapatinib was from GlaxoSmithKline (Hertfordshire, United
Kingdom). The anti-HER2 mouse mAb FRP5 was kindly provided
by N. Hynes (FMI, Basel, Switzerland). The F(ab′)2 fragments of
cetuximab and trastuzumab were prepared by pepsin digestion as
described [13]. Absence of undigested, intact mAbs was checked
by SDS-PAGE.
Cell Lines and Culture
BxPC-3 and SKOV-3 cell lines were obtained from the ATCC
(Rockville, MD). The Capan-1 cell line was kindly provided by
Pr L. Buscail (Toulouse, France). All cell lines were maintained in the
appropriate medium supplemented with 10% fetal calf serum, 50 U/ml
penicillin, and 50 μg/ml streptomycin.
EGFR and HER2 Cell Surface Quantification
Cell surface expression of EGFR andHER2 in BxPC-3 and Capan-1
cells was quantified using the Quantitative Immuno-Fluorescence In-
direct assay (QIFI kit; Dako, Copenhagen, Denmark) as described
[14]. Briefly, cells were first labeled with anti-EGFR and anti-HER2
antibodies before adding an FITC-conjugated antimouse immuno-
globulin G reagent (Sigma-Aldrich, St Louis, MO). The fluorescent
standards (known calibration beads) were concurrently labeled with
the same FITC-conjugated secondary antibody. The fluorescence inten-
sity of the different standards was used to calculate the standard regres-
sion curve between fluorescence intensity and antigen density, expressed
as the antibody binding capacity in molecules per cell. Samples were
analyzed with a Coulter Epics XL-MCL Flow Cytometer (Beckman
Coulter, Fullerton, CA).
Cell Proliferation Assay and IC50 Determination
The effect of the different TKIs on cell viability was evaluated
using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H tetrazolium (MTS) and the electron coupling reagent
phenazine methosulfate (PMS). Briefly, BxPC-3 and Capan-1 cells
were cultured in 96-well microtiter plates at 10,000 cells/well. After
24 hours, cells were treated with TKI at concentrations ranging from
0.001 to 20 μg/ml for erlotinib or from 0.001 to 20 μM for lapatinib.
After a 96-hour incubation, cells were exposed to MTS/PMS and in-
cubated at 37°C for 2 hours. Absorbance was measured at 490 nm,
and the half-maximal inhibitory concentration (IC50) values were cal-
culated as the percentage of proliferating cells relative to untreated cells.
All experiments were performed in triplicate.
EGFR and HER2 Dimer Analysis
EGFR/HER2 dimers were quantified using an antibody-based
TR-FRET assay, as described [14]. Capan-1 or BxPC-3 cells were
plated at 3 × 105 cells/well in 96-well sterile black microplates in Dul-
becco modified Eagle medium (without phenol red) supplemented
with 10% fetal calf serum and incubated overnight. Cells were treated
with the two mAbs, TKIs alone, or erlotinib plus trastuzumab for
10 minutes at 37°C. After washing in KREBS buffer, cells were then
fixed in 10% formalin for 2 minutes and washed once with KREBS
buffer. Cells were labeled with 10 nM the anti-EGFR mAb m425
and 1 nM the anti-HER2 mAb FRP5 (both diluted in KREBS buffer),
coupled to d2 (acceptor) and Lumi4 Tb cryptate (donor) dyes, respec-
tively (Cisbio Bioassays, Bagnol-sur-Cèze, France) at 37°C for 6 hours.
These two mouse mAbs are directed to different epitopes on the recep-
tors than those targeted by the therapeutic antibodies trastuzumab and
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cetuximab, and thus, no interference was observed in the TR-FRET
assay (data not shown). After four washes in KREBS buffer, the fluo-
rescence of the Lumi4 Tb and d2 dyes was measured, respectively,
at 620 and 665 nm emission (F665) (60-μs delay, 400-μs integration)
on 337 nm excitation, on a Pherastar FS instrument (BMG Labtech,
Offenburg, Germany).
The TR-FRET signal was expressed as ΔF665(%) = ΔF665 /
F665Tb, with ΔF665 = F665c − F665Tb, as previously explained
[14], and then data were presented considering the untreated sample
as having 100% dimerization. The TR-FRET signal expressed as the
percentage of dimers was correlated with the EGFR/HER2 hetero-
dimer quantity normalized to the HER2 quantity. The 620-nm
time-resolved fluorescence emission was correlated with the HER2
quantity. At the same time, the prompt fluorescence of the d2 dye
was measured at 670 nm on a 620-nm excitation to quantify the
EGFR receptors.
The same type of experiments was performed to detect EGFR
homodimers and HER2 homodimers using 10 nM m425-Lumi4
Tb plus 10 nM m425-d2 and 1 nM FRP5-Lumi4 Tb plus 1 nM
FRP5-d2, respectively. In the case of homodimers, the TR-FRET
signal was correlated with the homodimer quantity normalized to
the targeted receptor quantity.
Tumor Xenografts and Treatment Procedure
All in vivo experiments were performed in compliance with the
French regulations and ethical guidelines for experimental animal
studies in an accredited establishment (agreement no. C34-172-27). Six-
week-old female athymic mice, purchased from Harlan (Le Malcourlet,
France), were injected subcutaneously into the right flank with BxPC-3
(3.5 × 106), Capan-1 (10 × 106), or SKOV-3 (5 × 106) cells. Tumor-
bearing mice were randomized in the different treatment groups
(10 animals per group) when tumors reached a minimum volume of
50 mm3. Tumor volumes calculated by the formula: D1 × D2 × D3 /
2. For survival comparison, mice were killed when tumor reached a
volume larger than 1000 mm3.
Mice were treated with the 2mAbs (trastuzumab/cetuximab) therapy
(ratio 1:1; 2 mg/kg of each mAb), trastuzumab (2 mg/kg)/erlotinib
(100 mg/kg), or lapatinib alone (100, 200, or 300 mg/kg). Erlotinib
and lapatinib were administrated daily through oral gavage, and anti-
bodies were given intraperitoneally twice a week. All animals were
treated for 4 weeks.
To determine the implication of the Fc part of the antibodies,
BxPC-3 cells were xenografted in the right flank of SCID/Beige mice
(Charles River, L’Arbresle, France), which lack NK cells. Mice were
treated with F(ab′)2 fragments of trastuzumab and cetuximab (ratio
1:1; 1.35 mg/kg of each fragment) daily (to compensate for their re-
duced half-life) for 4 weeks or with intact trastuzumab and cetuximab
(ratio 1:1; 2 mg/kg) twice a week. The concentration of fragments was
adjusted to 2 μM like for the intact antibodies. Tumor dimensions and
body weight were measured twice weekly.
Western Blot Analysis
At days 2, 7, and 15 after the beginning of treatment, tumors were
harvested and lysed with buffer (150 mM NaCl, 10 mM Tris pH
7.4, 1 mM EDTA, 1% Triton X-100) containing 2 mM phenyl-
methylsulfonyl fluoride, 100 mM sodium fluoride, 10 mM sodium
orthovanadate, and one tablet of complete protease inhibitor mix-
ture (Sigma, St Louis, MO). Proteins were separated on 7% or 10%
SDS-PAGE gels under reducing conditions and transferred onto poly-
vinylidene difluoride membranes (Millipore, Bedford, MA), which
were then saturated in phosphate-buffered saline (PBS) containing
0.1% Tween-20 and 5% nonfat dry milk. Membranes were incu-
bated with the appropriate dilutions of polyclonal rabbit antihuman
EGFR, -HER2, -ERK1/2, -AKT, and -phosphorylated ERK1/2 or
-AKT antibodies (Cell Signaling Technology, Beverly, MA). The
level of tyrosine phosphorylation in tumors was analyzed using the
anti–phosphotyrosine 4G10 antibody. Immunoblots were normalized
using an antibody directed to glyceraldehyde-3-phosphate dehydro-
genase (Millipore).
Antibody-Dependent Cell Cytotoxicity Assay by
Chromium Release
Briefly, 2 × 105 BxPC-3 cells (target) were incubated with 100 μCi
of 51Cr (Perkin-Elmer, Boston, MA) and 10 μg/ml of whole anti-
bodies or F(ab′)2 fragments at 37°C for 1 hour. After three washes,
cells were cultured in 96-well plates. Ficoll-purified human peripheral
blood mononuclear cells (EFS, Montpellier, France), as effectors cells,
were added at various effector-target (E /T ) ratios. After 4 hours of
incubation (37°C at 5% CO2), 100 μl of supernatant/well was recov-
ered, and radioactivity was measured using a gamma counter. Spon-
taneous release was determined by incubating target cells alone, and
maximal release was obtained by lysis of the target cells using 0.1 M
HCl. The percentage of specific lysis was calculated as 100 × [(experi-
mental release − spontaneous release) / (maximal release − spontaneous
release)]. All measurements were done in triplicates.
Statistical Analysis
A linear mixed regression model was used to determine the relation-
ship between tumor growth and the number of days after implanta-
tion. The fixed part of the model included variables corresponding
to the number of days after implantation and to the different groups.
Interaction terms were built into the model. Random intercept and
random slope were included to take into account the time effect. The
coefficients of the model were estimated by maximum likelihood and
considered significant at the 0.05 level.
Kaplan-Meier survival estimates were calculated from the date of the
xenograft until the date of the event of interest (i.e., tumor volume
of 1000 mm3) and compared using the log-rank test. The statistical
analysis was performed using the STATA 11.0 software (StataCorp
[2009] Stata Release 11, Statistical Software; StataCorp LP, College
Station, TX).
The statistical analysis of the data from the TR-FRET assay was
performed using the Prism GraphPad software (San Diego, CA).
Results
In Vitro, the HER2low Pancreatic Carcinoma Cell Lines
BxPC-3 and Capan-1 Are Sensitive to the EGFR TKI
Erlotinib and the Dual EGFR/HER2 TKI Lapatinib
To compare the effects of the 2mAbs therapy (cetuximab and
trastuzumab) and those of the erlotinib/trastuzumab combination
and of lapatinib alone, first we assessed the expression of EGFR and
HER2 in the human pancreatic carcinoma cell lines BxPC-3 and
Capan-1. EGFR expression was high in BxPC-3 cells (20.3 × 104
receptors/cell) and moderate in Capan-1 cells (2.7 × 104), whereas
HER2 expression was low in both cell lines, with 1.1 and 1.6 ×
104 receptors per cell, respectively (Table 1).
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The twoTKIs lapatinib and erlotinib showed different antiproliferative
effects. The IC50 for lapatinib (dual EGFR/HER2 TKI) was low with
values of 11.5 μM in BxPC-3 cells and 13.2 μM in Capan-1 cells. Con-
versely, the IC50 for erlotinib (EGFR TKI) was higher in both cell lines
(37.5 μM in BxPC-3 and 41.4 μM in Capan-1 cells), despite a 10-fold
difference in EGFR expression (Table 1).
Combined Erlotinib/Trastuzumab Treatment Inhibits
Tumor Progression in Mice Xenografted with BxPC-3
Cells, but Not in Mice Xenografted with Capan-1 Cells
The efficacy of the dual anti-EGFR/HER2 strategy using erlotinib
plus trastuzumab in comparison to the 2mAbs therapy (cetuximab/
trastuzumab) was evaluated in mice xenografted (n = 10 for each group)
with either BxPC-3 (wild-type K-ras) or Capan-1 (mutated K-ras),
using 100 mg/kg erlotinib because a dose of 150 mg/kg was associated
with important weight loss (data not shown). For trastuzumab, a
2-mg/kg dose was chosen on the basis of previous experiments [6].
No weight loss was observed in control animals and mice treated with
the 2mAbs therapy, whereas the group treated with the erlotinib/
trastuzumab combination showed weight loss (probably due to the
TKI); however, weight was partially recovered by the end of the ex-
periment. In Capan-1 model, the weight loss was slightly lower because
the maximum loss was 13% if we compared the erlotinib/trastuzumab–
treated mice to the control mice (Figure 1A). This value being 18% in
the BxPC3 model (Figure 1B).
In mice xenografted with Capan-1 cells and treated with the 2mAbs
therapy, tumor growth and volume were markedly reduced (mean
tumor volume of 300 ± 30 mm3 at the end of the experiment) in
comparison to controls (1000 ± 200 mm3, P < .001; Figure 1C ).
The therapeutic benefit was significant with a longer median survival
than controls (34 days longer; P = .0107) and 20% survival (Table 2).
In contrast, the erlotinib/trastuzumab combination had almost no
effect on tumor growth (Figure 1A), with no tumor-free mice and
no significant difference in median growth delay relative to controls
(P = .25; Table 2).
In mice xenografted with BxPC-3 cells, the 2mAbs therapy again
induced a marked inhibition of tumor growth (Figure 1D) and a
significantly higher delay of tumor progression compared with con-
trols (P < .0001) (Table 2). Conversely, in this model, the erlotinib/
trastuzumab combination also inhibited efficiently tumor growth
(Figure 1B) with a significant therapeutic benefit of 23 days in com-
parison to controls (P < .001; Table 2). The therapeutic advantage
of the 2mAbs therapy relative to the erlotinib/trastuzumab associa-
tion was demonstrated by the significant (P = .05) difference of mean
tumor volume (243 and 733 mm3, respectively) at the end of the
Figure 1. Comparison of the antitumor activity of the 2mAbs therapy (cetuximab/trastuzumab) and of the erlotinib/trastuzumab combination
in nude mice xenografted subcutaneously with Capan-1 and BxPC-3 human pancreatic carcinoma cells. The weight of the animals was
followed up during treatment in the Capan-1 (A) and BxPC-3 (B) xenograft models. At days 14 (Capan-1 cells) (C) and 26 (BxPC-3 cells)
(D) after graft, groups of 10 mice were treated with the two mAbs (ratio 1:1; 2 mg/kg of each mAb, twice a week), erlotinib (100 mg/kg;
daily) plus trastuzumab (2mg/kg, twice a week), or sterile PBS (daily). Results are presented as themean tumor volume for each group. Bars,
SD of the mean. C + T indicates cetuximab/trastuzumab; E + T, erlotinib/trastuzumab.
Table 1. Expression Level of EGFR and HER2 Receptors and IC50 of TKI Lapatinib and Erlotinib
on BxPC3 and Capan-1 Pancreatic Cell Lines.
Cell Line K-ras Status Molecules/Cell (×10-4) IC50 (μM)
EGFR HER2 Lapatinib Erlotinib
BxPC3 WT 20.3 ± 1.4* 1.1 ± 1.0 11.5 ± 0.9 37.5 ± 2.0
Capan-1 Mutated 2.7 ± 0.4 1.6 ± 1.5 13.2 ± 1.1 41.4 ± 1.6
Values are mean ± SE.
*Quantification was done using the QIFI kit. Antigen density was expressed as antibody-binding
capacity in molecules per cell.
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experiment (64 days after graft) and in the number of tumor-free mice
(3/10 and 0/10).
Unlike the 2mAbs Therapy, Lapatinib Has No Effect on
Tumor Progression in Mice Xenografted with BxPC-3
or Capan-1 Cells
As a third strategy to simultaneously inhibit EGFR and HER2, we
then evaluated the dual EGFR-HER2 TKI lapatinib. Mice xeno-
grafted with BxPC-3 or Capan-1 cells were treated with three relatively
high doses of lapatinib (100, 200, and 300 mg/kg) orally twice per day
or with the 2mAbs therapy (2 mg/kg) twice per week (n = 10 for each
group). No weight loss or toxicity was observed with the three doses
in the two xenograft models. Whereas 100 and 200 mg of lapatinib
had no effect in both models, 300 mg/kg lapatinib was associated with
a transient and moderate, but significant (P = .04) tumor growth
inhibition in mice xenografted with BxPC-3 cells (Figure 2A) but
not in those grafted with Capan-1 cells (Figure 2B). The efficiency
of the 2mAbs therapy was again confirmed in the parallel experiments
(Figure 2, A and B, and Table 2).
To verify that the moderate effect of lapatinib was not due to the
chosen regimen, we xenografted mice with SKOV-3 human ovarian
carcinoma cells, known to strongly express HER2, and treated them
with 100 or 300 mg/kg lapatinib orally twice a day or with the 2mAbs
therapy for 4 weeks. In this xenograft model, lapatinib showed a sig-
nificant dose-dependent inhibition of tumor growth (P < .0001 with
100 mg/kg and P < .0001 with 300 mg/kg) in comparison to un-
treated controls; however, rapid tumor escape was observed after the
end of the treatment (day 44; Figure 2C). In contrast, in mice treated
with the 2mAbs therapy, tumor growth inhibition was maintained
until the end of the experiment (Figure 2C ) with 80% of tumor-free
animals confirming our previous observation [6].
Coinjection of Cetuximab and Trastuzumab F(ab′)2
Fragments Is Sufficient to Obtain the Antitumor
Effects of the 2mAbs Therapy during Treatment
Unlike TKIs, mAbs can have Fc-dependent antitumor effects
through activation of effector cells by antibody-dependent cell-
mediatedcytotoxicity (ADCC). To determine to which extent the anti-
body binding site reactivity with the receptors was implicated in the
observed therapeutic synergy, F(ab′)2 fragments from cetuximab
and trastuzumab were prepared, and their antitumor effect was tested
in vitro and in vivo. As expected, intact mAbs induced an ADCC against
51Cr-labeled BxPC-3 tumor cells that was dependent on the effector/
target cells ratio (Figure 3A). Because BxPC-3 cells express more EGFR
than HER2 receptors at the cell surface, a higher percentage of lysis
was observed with cetuximab than with trastuzumab, and its effect
was comparable to what obtained using the two mAbs together. Con-
versely, the F(ab′)2 fragments obtained by pepsin digestion of the Fc
of the two mAbs did not induce ADCC even in the presence of an
excess of effector cells (Figure 3A).
Then, highly immunodeficient SCID/Beige mice, which lack ef-
fector cells such as NK cells and monocytes (Croy BA), were xeno-
grafted with BxPC-3 cells and treated by daily injection, because of
their shorter half-lives [15], of ADCC-inefficient F(ab′)2 fragments
from the two mAbs, or biweekly injection of intact cetuximab or
trastuzumab for 28 days. Similar significant tumor growth inhibition
was obtained with the F(ab′)2 fragments and the intact mAbs during
the treatment (Figure 3A), with a mean tumor volume of 200 ±
30 mm3 in comparison to 1100 ± 350 mm3 for the untreated control
group at day 48 after graft (Figure 3B). However, tumor escape was
Figure 2. Comparison of the effect of lapatinib (dual HER2/EGFR
TKI) and of the 2mAbs therapy on tumor growth in nude mice
xenografted subcutaneously with BxPC-3 (A), Capan-1 (B), or
SKOV-3 (C) cells and randomized in different groups (n = 10 per
group). At days 14 (Capan-1), 20 (BxPC-3), and 11 (SKOV-3 cells)
after graft, mice were treated with lapatinib (100, 200, or 300 mg/
kg, daily), the 2mAbs therapy (ratio 1:1; 2 mg/kg of each mAb, twice
per week) or sterile PBS (daily). Results are presented as the mean
tumor volume of each group. Bars, SD of the mean. C indicates
cetuximab; Lap, lapatinib; T, trastuzumab.
Table 2. Median Survival and Therapeutic Benefit of BxPC3 and Capan-1 Xenografted Mice
Treated with TKI and/or Monoclonal Antibodies.
Xenograft Treatment Median (day)* Median (day)† Tumor Free (%)
Capan-1 Control 38 0
Erlotinib + trastuzumab 57 +19 0
Lapatinib 200 mg/kg 38 0 0
Lapatinib 300 mg/kg 50 +12 0
Cetuximab + trastuzumab 72 +34 2/10 (20%)
BxPC3 Control 56 0
Erlotinib + trastuzumab 79 +23 0
Lapatinib 200 mg/kg 56 0 0
Lapatinib 300 mg/kg 56 0 0
Cetuximab + trastuzumab 102 +46 3/10 (30%)
*Median: days after graft where 50% of mice reach to a 1000-mm3 tumor volume.
†Benefit = (median of the different treatments − median of the control group).
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observed immediately after the end of the treatment with the F(ab′)2
fragments, probably because of their very short half-life. Conversely,
growth inhibition was still maintained 25 days after the end of the
treatment with the intact mAbs.
Taken together, these results demonstrate that the effect of the
2mAbs therapy is, at least, partly Fc independent and, therefore,
due to the induction of downstream signaling after the direct inter-
action of the antibodies with the receptors expressed at the tumor
cell surface.
Only the 2mAbs Therapy Induces Long-term EGFR/HER2
Down-regulation and Inhibition of AKT Phosphorylation
in Capan-1 Cell Xenografts
Downstream signaling from the EGFR/HER2 receptors activates
several key signaling cascades, including the AKT andmitogen-activated
protein kinase (MAPK) activation pathways [9]. To determine the
in vivomechanisms underlying the different efficacy of the various dual
anti-EGFR/HER2 strategies, we analyzed EGFR/HER2 expression
and AKT/MAPK phosphorylation in Capan-1 cells harvested from
xenografted nude mice at different time points (days 2, 7, and 15) after
the beginning of the mAb- and TKI-based treatments. The 2mAbs
therapy induced a long-term and marked decrease in both EGFR and
HER2 expression at all tested time points. Conversely, lapatinib was
associated with a strong increase in HER2 expression at all time points.
Treatment with erlotinib plus trastuzumab was followed by EGFR
down-regulation mainly at day 2 after treatment, but not at later times,
whereas the reduction in HER2 expression was more persistent, cer-
tainly due to trastuzumab (Figure 4A). The second marked and long-
term effect of the 2mAbs therapy was the specific decrease in AKT
phosphorylation, but not total AKT, at all tested time points (Fig-
ure 4A). In contrast, erlotinib/trastuzumab and lapatinib alone did not
induce such effect (Figure 4A). No effect on MAPK phosphorylation
Figure 3. Comparison of the antitumor effect, in vitro and in vivo,
of the 2mAbs therapy (cetuximab and trastuzumab) using intact
mAbs or the F(ab′)2 fragments. (A) ADCC was assessed in vitro by
incubating 51Cr-labeled BxPC-3 target cells with peripheral blood
mononuclear cells (effector cells) at different concentrations in
the presence of cetuximab and/or trastuzumab (whole mAbs) or
their F(ab′)2 fragments. ADCC was determined by measuring the
51Cr released in the supernatant. (B) SCID/Beige mice bearing
BxPC-3 pancreatic carcinoma xenografts were treated at day 20
after graft by daily coinjection of F(ab′)2 fragments of the two mAbs
or twice per week with the intact mAbs. Results are presented as
the mean tumor volume of each treated group. Bars, SD of the
mean. C indicates cetuximab; double-head arrow, period of treat-
ment; T, trastuzumab. Figure 4. (A) The 2mAbs therapy induces long-term EGFR and
HER2 down-regulation and inhibition of AKT phosphorylation in
Capan-1 pancreatic carcinoma cells. Mice bearing Capan-1 xeno-
grafts were treated with the 2mAbs (cetuximab/trastuzumab)
therapy (ratio 1:1; 2 mg/kg of each mAb, twice a week), erlotinib
(100 mg/kg, daily) plus trastuzumab (2 mg/kg, twice per week), or
lapatinib (300 mg/kg, daily). Tumors were resected at day 2, 7, or
15 after the beginning of treatment. Cell lysates were analyzed
by Western blot analysis for EGFR and HER2, total AKT, phos-
phorylated AKT, total MAPK, and phosphorylated MAPK ex-
pression. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
served as loading control. C + T indicates 2mAbs. (B) The 2mAbs
therapy induces long-term inhibition of the overall tyrosine phos-
phorylation profile in Capan-1 tumor cells, whereas the tested TKIs
did not. Mice xenografted with Capan-1 pancreatic carcinoma cells
were treated with either the two mAbs therapy (ratio 1:1; 2 mg/kg
of each mAb, twice per week), erlotinib (100 mg/kg, daily) plus tras-
tuzumab (2 mg/kg, twice per day), or lapatinib (300 mg/kg, daily).
Tumors were resected at day 2, 3, or 7 after beginning the mAbs
therapy and at 1 hour, 6 hours, 7 days, and 15 days after the begin-
ning of the treatment with erlotinib/trastuzumab or lapatinib. Cell
lysates were analyzed by Western blot analysis for tyrosine phos-
phorylation (P-Tyr). C + T indicates cetuximab/trastuzumab; E + T,
erlotinib/trastuzumab.
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and on the level of total MAPK was noted after the different treatments
(Figure 4A). This result could be expected due to the mutated K-ras
status of the Capan-1 cell line.
The 2mAbs Therapy Induces Long-term Inhibition
of Tyrosine Phosphorylation Unlike the Two Other
Dual Anti-EGFR/HER2 Treatments
The overall tyrosine phosphorylation profile of Capan-1 cells har-
vested from xenografted nude mice at days 2, 7, and 15 after the
beginning of the different treatments was analyzed with Western blot
analysis. The 2mAbs therapy induced long-term blockade of tyrosine
phosphorylation from day 2 to day 7 in comparison to untreated
controls (Figure 4B). Conversely, the erlotinib/trastuzumab com-
bination and lapatinib alone induced only short-term inhibition, one
hour after the beginning of treatment. These data support the notion
of a prompt TKI effect on tyrosine phosphorylation in contrast to the
persistent effect after the 2mAbs therapy.
Incubation of BxPC-3 Cells with Cetuximab and Trastuzumab
Is Associated with Higher Disruption of EGFR/HER2
Dimerization and Homodimer Formation than Incubation
with Erlotinib/Trastuzumab or Lapatinib
Using a recently described antibody-based TR-FRET assay that
allows the detection of EGFR/HER2 heterodimerization [14], we
analyzed the effect on EGFR/HER2 dimerization of a 10-minute
incubation of BxPC-3 cells with cetuximab/trastuzumab, erlotinib/
trastuzumab, or lapatinib alone. The BxPC-3 pancreatic carcinoma line
was chosen for this analysis because it expresses more EGFR/HER2
heterodimers than the Capan-1 cell line, thus allows obtaining a better
fluorescence signal to accurately follow heterodimer formation (Fig-
ure 5A). A significant dose-dependent disruption of EGFR/HER2
heterodimerization (approximately 50%) was observed when BxPC-3
cells were incubated with the two mAbs in comparison to untreated
cells (P < .0001). The lower fluorescence signal was not due to steric
hindrance by the two therapeutic mAbs because the labeled mAbs
used in the FRET assay were directed to different EGFR and HER2
epitopes. Indeed, binding to the target cells and fluorescent signal (at
620 and 670 nm) of the two labeled mAbs were not inhibited by pre-
incubation with the two mAbs. Incubation with erlotinib/trastuzumab
or lapatinib also disrupted EGFR/HER2 heterodimerization but to a
lower extent (38% maximal disruption, P < .001; and 14% maximal
disruption, P > .05). Finally, preincubation with an irrelevant mAb did
not influence dimer formation and fluorescence emission at 670 and
620 nm (Figure 5B). As expected, erlotinib alone did not disturb
EGFR/HER2 heterodimerization at doses ranging from 30 nM to
30 μM, whereas trastuzumab alone induced a dose-dependent inter-
ference of EGFR/HER2 dimerization (up to 38% disruption at the
dose of 5 μg/ml; data not shown). This suggests that the disruption of
EGFR/HER2 heterodimerization induced by the erlotinib/trastuzumab
combination is mainly due to the effect of trastuzumab. Preincubation
with the two mAbs did not modify EGFR and HER2 expression. An
increase in EGFR homodimers was observed after preincubation with
the two mAbs, but not with the TKIs, in comparison to untreated cells.
Conversely, HER2 homodimers were increased both by preincubation
with the mAbs and with erlotinib/trastuzumab, mainly because of the
effect of trastuzumab (data not shown).
These results indicate that incubation of BxPC-3 cells with cetuximab/
trastuzumab modifies the repartition of homodimers and heterodimers
at the cell surface with disruption of EGFR/HER2 heterodimerization
and increased homodimer formation.
Discussion
In previous studies, we demonstrated the synergistic effect of com-
bining an anti-EGFR mAb (cetuximab) and an anti-HER2 mAb
Figure 5. Effect of the 2mAbs (cetuximab/trastuzumab) therapy, of
erlotinib plus trastuzumab, or of lapatinib alone on receptor hetero-
dimerization and homodimerization using the antibody-based
TR-FRET assay. (A) Quantification of EGFR/HER2 heterodimers in
Capan-1 and BxPC-3 cells. (B) BxPC-3 cells were treated with
increasing concentrations of cetuximab/trastuzumab (ratio 1:1),
erlotinib and/or trastuzumab, or lapatinib for 10 minutes and then
fixed in 10% formalin. Fixed cells were then incubated with d2-
labeled anti-EGFR and lumi4-terbium–labeled anti-HER2 mAbs
(directed against different epitopes than the ones recognized by
cetuximab and trastuzumab) for 6 hours. Cells were washed, and
the TR-FRET signals were measured at 665 nm in the TRF mode
(60-μs delay, 400-μs integration) on 337 nm excitation to estimate
the dimer level. The TR-FRET signal was expressed as ΔF665 (%)
and then as the dimer percentage (see Materials and Methods).
(C) Effect of the different therapies on EGFR or (D) HER2 homodimer
formation. Data are mean ± SEM of three independent experiments
performed in triplicate. ****P < .0001; ***P < .001, by two-way
analysis of variance, with Bonferroni multiple-comparison post test
(each treatment was compared with the irrelevant mAb treatment).
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(trastuzumab) for pancreatic cancer treatment (2mAbs therapy). In the
present study, we wanted to evaluate two other dual anti-EGFR/
HER2 strategies involving TKIs (the combination of erlotinib with
trastuzumab and the EGFR/HER2 TKI lapatinib) and compare them
with the 2mAbs therapy. With up to 30% complete remission, the
2mAbs therapy (trastuzumab and cetuximab) had the greatest anti-
tumoral effect in nude mice xenografted with two human HER2low
pancreatic carcinoma cell lines, independently of their K-ras status.
The therapeutic benefit of this treatment was associated with a marked
and sustained down-regulation of EGFR/HER2 receptors as well as a
downstream reduction of AKT phosphorylation. Moreover, the sig-
nificant therapeutic benefit obtained with F(ab′)2 fragments of the
two mAbs (Figure 3) clearly indicates that the observed antitumor
effect must be due, at least in part, to the interaction of the binding
part of the mAbs with the two receptors and the induced intracellular
signaling [9]. This is in disagreement with the work by Clynes et al.
[16] who, on the basis of the negative therapeutic effect of trastuzumab
or anti-CD20 mAbs in Fcγ receptor KO mice, attributed most of the
antitumor effect of the mAbs to an ADCC mechanism. However,
these authors xenografted mice with HER2high BT474M1 tumor cells
and treated them with trastuzumab alone. Although in our study the
F(ab′)2 fragments were as efficient as the intact mAbs during the treat-
ment period, tumors rapidly relapsed after the end of the treatment
with fragments but not with intact mAbs. The sustained antitumor
effect of intact mAbs suggests an implication of immune effector cells
and was, therefore, very surprising because these experiments were
performed in SCID/Beige mice, which lack NK cells, the major ef-
fector cells responsible for the ADCC mechanism. The continuous
effect could thus be attributed to monocytes. The rapid tumor relapse
after treatment with F(ab′)2 could also be explained by the very short
half-life of the fragments owing to their lack of reactivity with the
FcRn receptors [17]. Indeed, during the treatment period, the differ-
ence in half-life between mAbs and F(ab′)2 was compensated by the
different schedules (twice a week for intact mAbs vs daily for F(ab′)2).
The erlotinib/trastuzumab combination induced marked tumor
growth inhibition in mice xenografted with wild-type K-ras (BxPC-3
cells), but not with mutated K-ras (Capan-1 cells) pancreatic carcinoma
cell lines, confirming the importance of the K-ras status in the response
to EGFR/HER2–targeted therapy. Indeed, K-ras is considered a reli-
able biomarker of the efficacy of EGFR-specific antibody therapy in
colorectal cancer patients [18], but its role as predictive biomarker re-
mained to be clarified in patients treated with the EGFR-specific TKI
erlotinib [19]. Moreover, the positive response of BxPC-3 xenografts to
erlotinib/trastuzumab despite the low HER2 expression of these cells is
very interesting because, previously, only HER2-overexpressing breast
cancer cells were reported to respond to the combination of trastuzu-
mab with gefitinib, another EGFR-specific TKI [20]. The limitation
of the erlotinib/trastuzumab combination is its toxicity certainly due
to the limited selectivity of erlotinib [21,22]. In our model, erlotinib-
treated mice lost up to 17% of their weight and did not fully recover
their initial weight 15 days after the end of the treatment.
HER3 expression is another parameter that is correlated with sen-
sitivity to erlotinib in five human pancreatic cancer cell lines [23]. The
erlotinib/trastuzumab–sensitive BxPC-3 cells strongly express HER3,
whereas the erlotinib/trastuzumab–insensitive Capan-1 cells do not. In
cells that strongly express HER3, erlotinib might indirectly inhibit
HER3 phosphorylation by EGFR-induced transactivation [24]. Con-
versely, in HER3-negative/low pancreatic carcinoma cells, the HER3/
PI3K/AKT pathway cannot be activated on EGFR/HER3 heterodimer
formation, and thus, they are less dependent on EGFR-induced sig-
naling and, consequently, not sensitive to erlotinib [23]. All these data
suggest that EGFR/HER3 coexpression could be a predictor of erlotinib
sensitivity in pancreatic cancer.
Lapatinib could have been an attractive alternative to the 2mAbs ther-
apy because this TKI acts specifically and simultaneously on EGFR and
HER2. Few preclinical studies have evaluated the potential of lapatinib
for the treatment of pancreatic cancer, and they reported a synergistic
effect when lapatinib was combined with 5-fluorouracil [25] or radio-
therapy [26]. Furthermore, Safran et al. [11] demonstrated that patients
with pancreatic cancer can be treated with the lapatinib/gemcitabine
combination without toxicity. However, here we show that lapatinib
on its own does not have any significant effect in mice xenografted with
the HER2low Capan-1 and BxPC-3 (HER2low) pancreatic cancer cells.
Conversely, the same doses of lapatinib efficiently inhibited tumor
growth in mice xenografted with the HER2high SKOV3 human ovarian
cancer cell line, confirming the correlation between high HER2 expres-
sion and therapeutic efficacy of lapatinib [27,28].
Half-life differences could explain, at least partially, the higher
efficacy of the 2mAbs therapy relative to the treatment with TKIs,
although this parameter was taken into account in the different regi-
mens (twice a week for intact mAbs vs twice a day for the TKIs). This
is illustrated by the tyrosine phosphorylation profile of Capan-1 cells in
which a rapid but very short phosphorylation inhibition was induced
by the erlotinib/trastuzumab combination and a persistent inhibition
by the two mAbs.
The cell signaling pathways induced by the different treatment were
investigated ex vivo in Caplan-1 (HER2low, K-ras mutated) pancreatic
tumor cells isolated from treated nude mice. The long-term down-
regulation of EGFR and HER2 receptors after the 2mAbs therapy
contrasted with the cell surface accumulation of HER2 receptors in
cancer cells isolated from mice treated with lapatinib, as previously de-
scribed in vitro and in vivo in HER2high breast cancer [29]. Ben-Kasus
et al. [30] reported that the combination of HER2-specific antibodies
had a stronger antitumoral effect through increased endocytosis and
degradation of HER2 target receptors. Our results confirm and extend
this observation because we show that concomitant EGFR and HER2
targeting has a clear antitumor effect and induces down-regulation of
both EGFR and HER2 receptors. In contrast to anti-EGFR/HER2
strategies using TKIs, the 2mAbs therapy blocked phosphorylation
of the AKT pathway, but did not affect MAPK activation, probably
due to the K-ras mutated status of Capan-1 cells. K-ras mutations are
known to result in impaired GTPase function, which locks K-ras in the
GTP-bound “on” state, triggering downstream activation pathways,
including particularly MAPK, and leading to a variety of cellular pro-
cesses, including cell survival and mobility [31]. MAPK, therefore,
could be an attractive therapeutic target, but a disappointing phase 2
trial of the MAPK inhibitor CI-1040 in pancreatic cancer stopped fur-
ther development [32]. Because the combined inhibition of MAPK
and EGFR using CI-1040 and gefitinib, respectively, was effective in
a preclinical study on pancreatic cancer [33], the association of aMAPK
inhibitor currently under clinical trial (e.g., GSK 1120212) with the
2mAbs therapy could improve our therapeutic strategy. Indeed, the re-
cent study by Meira et al. [34] described a synergistic effect between
the MAPK inhibitor PD98059 and cetuximab on cell proliferation
and downstream signaling in cervical cancer cells.
Finally, we used our newly developed antibody-based TR-FRET
assay [14] to analyze the importance of EGFR/HER2 heterodimer
disruption by the different therapies. The 2mAbs therapy has a major
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effect with 49% disruption compared with 14% for lapatinib. This
observation is of importance because cross talk between the four re-
ceptors of the HER family was shown to contribute to a more aggres-
sive phenotype and to affect response to therapy in many cancers
[35]. Furthermore, we observed a significant increase in homodimers
in cells incubated with the two mAbs in comparison to untreated
cells or after incubation with the TKIs. We can hypothesize that
the two mAbs cetuximab and trastuzumab first perturb the ligand-
induced heterodimerization process and then promote homodimer
formation. Because of their bivalence, mAbs can favor the formation
of receptor homodimers, which are preferentially internalized and
degraded. As already described, EGFR homodimers are rapidly endo-
cytosed in response to EGF stimulation and degraded [36], whereas
HER2 undergo slow endocytosis, followed by recycle to the cell
surface [37]. EGFR/HER2 dimer formation is thus impaired by EGF-
induced endocytosis, resulting in extended activation [38] and increased
heterodimer recycling at the cell surface [39].
In conclusion, in the present in vivo study, we demonstrate that the
2mAbs therapy, in which cetuximab is combined with trastuzumab, is
more efficient than treatments with TKIs (erlotinib with trastuzumab
or lapatinib alone). The efficacy of the 2mAbs therapy is based on the
downstream inhibition of AKT phosphorylation and on EGFR/HER2
heterodimer disruption linked to an increase in EGFR and HER2
homodimer formation. These direct effects are associated with the
involvement of immune cells to induce ADCC. These results support
the ongoing clinical investigation on the effects of the 2mAbs therapy
in patients with metastatic pancreatic carcinomas (independently of
their K-ras status) and the rationale for using mAb combinations in
therapeutic oncology.
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